

## 11 February 2022

Ms Michaels

The Society of Hospital Pharmacists of Australia (SHPA)

## RE. UPDATED NOTIFICATION ON SUPPLY SHORTGAES FOR YERVOY (IPILIMUMAB) AND OPDIVO (NIVOLUMAB)

Dear Ms Michaels,

On behalf of Bristol-Myers Squibb Australia Pty Ltd (BMS) I am writing to provide you a further update regarding Yervoy (Ipilimumab) and Opdivo (Nivolumab) supply shortages as outlined below:

## **Product Stock Status, 11 February 2022**

BMS Code	BMS Product	Stock Status	<b>Anticipated Resolution</b>
1279684	YERVOY SINJ 200MG (1VLX40ML) AU/NZ	Confirmed out of stock	Week commencing 14 March 2022
1279683	YERVOY SINJ 50MG (1VLX10ML) AU/NZ	In stock. Anticipated out of stock week commencing 28 February 2022	Week commencing 14 March 2022

BMS Code	BMS Product	Stock Status	Anticipated Resolution
1394080	OPDIVO SINJ 40MG (1VLX4ML) AU	In stock. Anticipated out of stock week commencing 21 February 2022	Week commencing 21 March 2022
1394152	OPDIVO SINJ 100MG (1VLX10ML) AU	In stock. Anticipated out of stock week commencing 7 March 2022	Week commencing 21 March 2022

These stock shortages are related to manufacturing logistics, supply constraints, demand surges, shipment delays and availability of raw materials. We are working to resolve this matter as soon as possible. BMS knows the importance of a steady and reliable supply of critical medicines for patients and remains committed to delivering this medicine to patients who need it.

BMS continues to update the Therapeutics Goods Administration (TGA) of any changes to current or anticipated supply shortages. As this is a dynamic situation please also refer to the TGA Medicine Shortage Database for up-to-date information <a href="https://apps.tga.gov.au/Prod/msi/search?shortagetype=All">https://apps.tga.gov.au/Prod/msi/search?shortagetype=All</a>.

If you have any questions relating to the shortage, please contact the BMS Medical Information Department at 1800 067 567 (option 2) or via email at: medinfo.australia@bms.com.

Yours sincerely,

Kate Church